Discovery and optimization of wt-RET/KDR-selective inhibitors of RET(V804M) kinase
Authors
Newton, RebeccaWaszkowycz, Bohdan
Seewooruthun, C
Burschowsky, D
Richards, M
Hitchin, Samantha
Begum, Habiba
Watson, Amanda J
French, Eleanor
Hamilton, Niall M
Jones, Stuart
Lin, LY
Waddell, Ian D
Echalier, A
Bayliss, R
Jordan, Allan M
Ogilvie, Donald J
Affiliation
Drug Discovery Unit, Cancer Research UK, Manchester Institute, University of Manchester, Alderley Park, Macclesfield SK10 4TG, U.K.Issue Date
2020
Metadata
Show full item recordCitation
Newton R, Waszkowycz B, Seewooruthun C, Burschowsky D, Richards M, Hitchin S, et al. Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RET(V804M) Kinase. ACS Med Chem Lett. 2020;11(4):497-505.Journal
ACS Medicinal Chemistry LettersDOI
10.1021/acsmedchemlett.9b00615PubMed ID
32292556Additional Links
https://dx.doi.org/ 10.1021/acsmedchemlett.9b00615Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1021/acsmedchemlett.9b00615
Scopus Count
Collections
Related articles
- Discovery of (wt) RET and (V804M) RET Inhibitors: From Hit to Lead.
- Authors: Mologni L, Dalla Via M, Chilin A, Palumbo M, Marzaro G
- Issue date: 2017 Aug 22
- Investigating natural compounds against oncogenic RET tyrosine kinase using pharmacoinformatic approaches for cancer therapeutics.
- Authors: Parate S, Kumar V, Chan Hong J, Lee KW
- Issue date: 2021 Dec 22
- Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
- Authors: La Pietra V, Sartini S, Botta L, Antonelli A, Ferrari SM, Fallahi P, Moriconi A, Coviello V, Quattrini L, Ke YY, Hsing-Pang H, Da Settimo F, Novellino E, La Motta C, Marinelli L
- Issue date: 2018 Apr 25
- Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.
- Authors: Yang J, Chen K, Zhang G, Yang QY, Li YS, Huang SZ, Wang YL, Yang W, Jiang XJ, Yan HX, Zhu JQ, Xiang R, Luo YF, Li WM, Wei YQ, Li LL, Yang SY
- Issue date: 2018 Jan 1
- Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
- Authors: Mologni L, Redaelli S, Morandi A, Plaza-Menacho I, Gambacorti-Passerini C
- Issue date: 2013 Sep 5